Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS-International Prognostic Index (CNS-IPI) risk model may improve identification of patients at high risk for developing secondary CNS disease. CNS relapse was analyzed in 1418 DLBCL patients treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy in the phase 3 GOYA study. Cell of origin (COO) was assessed using gene-expression profiling. BCL2 and MYC protein expression was analyzed by immunohistochemistry. The impact of CNS-IPI, COO, and BCL2/MYC dual-expression status on CNS relapse was assessed using a multivariate Cox regression model (data available in n = 1418, n = 933, and n = 688, respectively). High CNS-IPI score (hazard ratio [HR], 4.0; 95% confidence interval [CI], 1.3-12.3; P = .02) and activated B-cell‒like (ABC) (HR, 5.2; 95% CI, 2.1-12.9; P = .0004) or unclassified COO subtypes (HR, 4.2; 95% CI, 1.5-11.7; P = .006) were independently associated with CNS relapse. BCL2/MYC dual-expression status did not impact CNS relapse risk. Three risk subgroups were identified based on the presence of high CNS-IPI score and/or ABC/unclassified COO (CNS-IPI-C model): low risk (no risk factors, n = 450 [48.2%]), intermediate risk (1 factor, n = 408 [43.7%]), and high risk (both factors, n = 75 [8.0%]). Two-year CNS relapse rates were 0.5%, 4.4%, and 15.2% in the respective risk subgroups. Combining high CNS-IPI and ABC/unclassified COO improved CNS relapse prediction and identified a patient subgroup at high risk for developing CNS relapse. The study was registered at www.clinicaltrials.gov as #NCT01287741.

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL / Klanova, M; Sehn, Lh; Bence-Bruckler, I; Cavallo, F; Jin, J; Martelli, M; Stewart, D; Vitolo, U; Zaja, F; Zhang, Q; Mattiello, F; Sellam, G; Punnoose, Ea; Szafer-Glusman, E; Bolen, Cr; Oestergaard, Mz; Fingerle-Rowson, Gr; Nielsen, T; Trneny, M.. - In: BLOOD. - ISSN 0006-4971. - 133:(2019), pp. 919-926. [10.1182/blood-2018-07-862862]

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.

Martelli M
Writing – Original Draft Preparation
;
2019

Abstract

Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS-International Prognostic Index (CNS-IPI) risk model may improve identification of patients at high risk for developing secondary CNS disease. CNS relapse was analyzed in 1418 DLBCL patients treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy in the phase 3 GOYA study. Cell of origin (COO) was assessed using gene-expression profiling. BCL2 and MYC protein expression was analyzed by immunohistochemistry. The impact of CNS-IPI, COO, and BCL2/MYC dual-expression status on CNS relapse was assessed using a multivariate Cox regression model (data available in n = 1418, n = 933, and n = 688, respectively). High CNS-IPI score (hazard ratio [HR], 4.0; 95% confidence interval [CI], 1.3-12.3; P = .02) and activated B-cell‒like (ABC) (HR, 5.2; 95% CI, 2.1-12.9; P = .0004) or unclassified COO subtypes (HR, 4.2; 95% CI, 1.5-11.7; P = .006) were independently associated with CNS relapse. BCL2/MYC dual-expression status did not impact CNS relapse risk. Three risk subgroups were identified based on the presence of high CNS-IPI score and/or ABC/unclassified COO (CNS-IPI-C model): low risk (no risk factors, n = 450 [48.2%]), intermediate risk (1 factor, n = 408 [43.7%]), and high risk (both factors, n = 75 [8.0%]). Two-year CNS relapse rates were 0.5%, 4.4%, and 15.2% in the respective risk subgroups. Combining high CNS-IPI and ABC/unclassified COO improved CNS relapse prediction and identified a patient subgroup at high risk for developing CNS relapse. The study was registered at www.clinicaltrials.gov as #NCT01287741.
2019
ELDERLY-PATIENTS; GENE-EXPRESSION; RISK-FACTORS; LYMPHOMA; RITUXIMAB; CHOP; CHEMOTHERAPY; IMPACT; SURVIVAL; MUTATION
01 Pubblicazione su rivista::01a Articolo in rivista
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL / Klanova, M; Sehn, Lh; Bence-Bruckler, I; Cavallo, F; Jin, J; Martelli, M; Stewart, D; Vitolo, U; Zaja, F; Zhang, Q; Mattiello, F; Sellam, G; Punnoose, Ea; Szafer-Glusman, E; Bolen, Cr; Oestergaard, Mz; Fingerle-Rowson, Gr; Nielsen, T; Trneny, M.. - In: BLOOD. - ISSN 0006-4971. - 133:(2019), pp. 919-926. [10.1182/blood-2018-07-862862]
File allegati a questo prodotto
File Dimensione Formato  
Klanova_cell-origin_2019.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 857.53 kB
Formato Adobe PDF
857.53 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1280165
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 85
social impact